Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder affecting millions worldwide. The patent is supported by data-driven in silico evidence and simulations generated by Cosmos Health’s AI-powered Cloudscreen drug repurposing platform, coupled with experimental validation. Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COSM:
- Cosmos Health secures rights, exclusive licensing for two anticancer drugs
- Cosmos Health secures exclusive distribution agreement with Virax Biolabs
- Cosmos Health appoints Dimitrios Trafalis as head of oncology
- Cosmos Health CEO, CFO collectively increase stake by 343,000 shares
- Cosmos Health files to sell common stock, warrants, no amount given
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue